{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:17:37Z","timestamp":1780481857983,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guiding Project of Hubei Provincial Health and Health Commission","award":["WJ2021F047"],"award-info":[{"award-number":["WJ2021F047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00066-022-01971-w","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:10:57Z","timestamp":1657631457000},"page":"1082-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a\u00a0single-center retrospective study"],"prefix":"10.1007","volume":"198","author":[{"given":"Rui","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Duo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longchao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-3474","authenticated-orcid":false,"given":"Fengjun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"3","key":"1971_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Laversanne\u00a0M, Soerjomataram\u00a0I, Jemal\u00a0A, Bray\u00a0F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1971_CR2","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.3747\/co.25.3732","volume":"25","author":"SM Abdallah","year":"2018","unstructured":"Abdallah\u00a0SM, Hirsh\u00a0V (2018) Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol 25(Suppl 1):S9\u2013S17. https:\/\/doi.org\/10.3747\/co.25.3732","journal-title":"Curr Oncol"},{"issue":"1","key":"1971_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck\u00a0FC, Boffa\u00a0DJ, Kim\u00a0AW, Tanoue\u00a0LT (2017) The eighth edition lung cancer stage classification. Chest 151(1):193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010","journal-title":"Chest"},{"key":"1971_CR4","doi-asserted-by":"publisher","first-page":"l5460","DOI":"10.1136\/bmj.l5460","volume":"367","author":"Y Zhao","year":"2019","unstructured":"Zhao\u00a0Y, Liu\u00a0J, Cai\u00a0X, Pan\u00a0Z, Liu\u00a0J, Yin\u00a0W, Chen\u00a0H, Xie\u00a0Z, Liang\u00a0H, Wang\u00a0W, Guo\u00a0Z, Zhao\u00a0S, Liang\u00a0W, He\u00a0J (2019) Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ 367:l5460. https:\/\/doi.org\/10.1136\/bmj.l5460","journal-title":"BMJ"},{"issue":"2","key":"1971_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s1470-2045(09)70364-x","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi\u00a0T, Morita\u00a0S, Yatabe\u00a0Y, Negoro\u00a0S, Okamoto\u00a0I, Tsurutani\u00a0J, Seto\u00a0T, Satouchi\u00a0M, Tada\u00a0H, Hirashima\u00a0T, Asami\u00a0K, Katakami\u00a0N, Takada\u00a0M, Yoshioka\u00a0H, Shibata\u00a0K, Kudoh\u00a0S, Shimizu\u00a0E, Saito\u00a0H, Toyooka\u00a0S, Nakagawa\u00a0K, Fukuoka\u00a0M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121\u2013128. https:\/\/doi.org\/10.1016\/s1470-2045(09)70364-x","journal-title":"Lancet Oncol"},{"issue":"3","key":"1971_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s1470-2045(11)70393-x","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell\u00a0R, Carcereny\u00a0E, Gervais\u00a0R, Vergnenegre\u00a0A, Massuti\u00a0B, Felip\u00a0E, Palmero\u00a0R, Garcia-Gomez\u00a0R, Pallares\u00a0C, Sanchez\u00a0JM, Porta\u00a0R, Cobo\u00a0M, Garrido\u00a0P, Longo\u00a0F, Moran\u00a0T, Insa\u00a0A, De Marinis\u00a0F, Corre\u00a0R, Bover\u00a0I, Illiano\u00a0A, Dansin\u00a0E, de Castro\u00a0J, Milella\u00a0M, Reguart\u00a0N, Altavilla\u00a0G, Jimenez\u00a0U, Provencio\u00a0M, Moreno\u00a0MA, Terrasa\u00a0J, Mu\u00f1oz-Langa\u00a0J, Valdivia\u00a0J, Isla\u00a0D, Domine\u00a0M, Molinier\u00a0O, Mazieres\u00a0J, Baize\u00a0N, Garcia-Campelo\u00a0R, Robinet\u00a0G, Rodriguez-Abreu\u00a0D, Lopez-Vivanco\u00a0G, Gebbia\u00a0V, Ferrera-Delgado\u00a0L, Bombaron\u00a0P, Bernabe\u00a0R, Bearz\u00a0A, Artal\u00a0A, Cortesi\u00a0E, Rolfo\u00a0C, Sanchez-Ronco\u00a0M, Drozdowskyj\u00a0A, Queralt\u00a0C, de Aguirre\u00a0I, Ramirez\u00a0JL, Sanchez\u00a0JJ, Molina\u00a0MA, Taron\u00a0M, Paz-Ares\u00a0L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a\u00a0multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246. https:\/\/doi.org\/10.1016\/s1470-2045(11)70393-x","journal-title":"Lancet Oncol"},{"issue":"10","key":"1971_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi\u00a0YK, Wang\u00a0L, Han\u00a0BH, Li\u00a0W, Yu\u00a0P, Liu\u00a0YP, Ding\u00a0CM, Song\u00a0X, Ma\u00a0ZY, Ren\u00a0XL, Feng\u00a0JF, Zhang\u00a0HL, Chen\u00a0GY, Han\u00a0XH, Wu\u00a0N, Yao\u00a0C, Song\u00a0Y, Zhang\u00a0SC, Song\u00a0W, Liu\u00a0XQ, Zhao\u00a0SJ, Lin\u00a0YC, Ye\u00a0XQ, Li\u00a0K, Shu\u00a0YQ, Ding\u00a0LM, Tan\u00a0FL, Sun\u00a0Y (2017) First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a\u00a0phase 3, open-label, randomized study. Annals of oncology: official journal of the European Society for. Med Oncol 28(10):2443\u20132450. https:\/\/doi.org\/10.1093\/annonc\/mdx359","journal-title":"Med Oncol"},{"issue":"2","key":"1971_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria\u00a0JC, Ohe\u00a0Y, Vansteenkiste\u00a0J, Reungwetwattana\u00a0T, Chewaskulyong\u00a0B, Lee\u00a0KH, Dechaphunkul\u00a0A, Imamura\u00a0F, Nogami\u00a0N, Kurata\u00a0T, Okamoto\u00a0I, Zhou\u00a0C, Cho\u00a0BC, Cheng\u00a0Y, Cho\u00a0EK, Voon\u00a0PJ, Planchard\u00a0D, Su\u00a0WC, Gray\u00a0JE, Lee\u00a0SM, Hodge\u00a0R, Marotti\u00a0M, Rukazenkov\u00a0Y, Ramalingam\u00a0SS (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N\u00a0Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"issue":"10","key":"1971_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/s1470-2045(13)70355-3","volume":"14","author":"Y Shi","year":"2013","unstructured":"Shi\u00a0Y, Zhang\u00a0L, Liu\u00a0X, Zhou\u00a0C, Zhang\u00a0L, Zhang\u00a0S, Wang\u00a0D, Li\u00a0Q, Qin\u00a0S, Hu\u00a0C, Zhang\u00a0Y, Chen\u00a0J, Cheng\u00a0Y, Feng\u00a0J, Zhang\u00a0H, Song\u00a0Y, Wu\u00a0YL, Xu\u00a0N, Zhou\u00a0J, Luo\u00a0R, Bai\u00a0C, Jin\u00a0Y, Liu\u00a0W, Wei\u00a0Z, Tan\u00a0F, Wang\u00a0Y, Ding\u00a0L, Dai\u00a0H, Jiao\u00a0S, Wang\u00a0J, Liang\u00a0L, Zhang\u00a0W, Sun\u00a0Y (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a\u00a0randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953\u2013961. https:\/\/doi.org\/10.1016\/s1470-2045(13)70355-3","journal-title":"Lancet Oncol"},{"issue":"11","key":"1971_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/jto.0000000000000648","volume":"10","author":"H Al-Halabi","year":"2015","unstructured":"Al-Halabi\u00a0H, Sayegh\u00a0K, Digamurthy\u00a0SR, Niemierko\u00a0A, Piotrowska\u00a0Z, Willers\u00a0H, Sequist\u00a0LV (2015) Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J\u00a0Thorac Oncol 10(11):1601\u20131607. https:\/\/doi.org\/10.1097\/jto.0000000000000648","journal-title":"J Thorac Oncol"},{"key":"1971_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2017.03.010","volume":"108","author":"SH Patel","year":"2017","unstructured":"Patel\u00a0SH, Rimner\u00a0A, Foster\u00a0A, Zhang\u00a0Z, Woo\u00a0KM, Yu\u00a0HA, Riely\u00a0GJ, Wu\u00a0AJ (2017) Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer 108:109\u2013114. https:\/\/doi.org\/10.1016\/j.lungcan.2017.03.010","journal-title":"Lung Cancer"},{"issue":"10","key":"1971_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jtho.2019.08.499","volume":"14","author":"P Peng","year":"2019","unstructured":"Peng P, Chen Y, Han G, Meng R, Zhang S, Liao Z, Zhang Y, Gong J, Xiao C, Liu X, Zhang P, Zhang L, Xia S, Chu Q, Chen Y, Zhang L (2019) MA01.09 concomitant SBRT and EGFR-TKI versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. J Thorac Oncol 14(10):S250-S251. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.499","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1971_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","volume":"13","author":"Q Xu","year":"2018","unstructured":"Xu\u00a0Q, Zhou\u00a0F, Liu\u00a0H, Jiang\u00a0T, Li\u00a0X, Xu\u00a0Y, Zhou\u00a0C (2018) Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKis. J\u00a0Thorac Oncol 13(9):1383\u20131392. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1971_CR14","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"AC Dingemans","year":"2019","unstructured":"Dingemans\u00a0AC, Hendriks\u00a0LEL, Berghmans\u00a0T, Levy\u00a0A, Hasan\u00a0B, Faivre-Finn\u00a0C, Giaj-Levra\u00a0M, Giaj-Levra\u00a0N, Girard\u00a0N, Greillier\u00a0L, Lantu\u00e9joul\u00a0S, Edwards\u00a0J, O\u2019Brien\u00a0M, Reck\u00a0M, Smit\u00a0EF, Van Schil\u00a0P, Postmus\u00a0PE, Ramella\u00a0S, Lievens\u00a0Y, Gaga\u00a0M, Peled\u00a0N, Scagliotti\u00a0GV, Senan\u00a0S, Paz-Ares\u00a0L, Guckenberger\u00a0M, McDonald\u00a0F, Ekman\u00a0S, Cufer\u00a0T, Gietema\u00a0H, Infante\u00a0M, Dziadziuszko\u00a0R, Peters\u00a0S, Porta\u00a0RR, Vansteenkiste\u00a0J, Dooms\u00a0C, de Ruysscher\u00a0D, Besse\u00a0B, Novello\u00a0S (2019) Definition of synchronous oligometastatic non-small cell lung cancer\u2014a consensus report. J\u00a0Thorac Oncol 14(12):2109\u20132119. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.025","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1971_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12885-020-6543-y","volume":"20","author":"K Liu","year":"2020","unstructured":"Liu\u00a0K, Jiang\u00a0G, Zhang\u00a0A, Li\u00a0Z, Jia\u00a0J (2020) Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer. BMC Cancer 20(1):76. https:\/\/doi.org\/10.1186\/s12885-020-6543-y","journal-title":"BMC Cancer"},{"issue":"9","key":"1971_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/s2213-2600(21)00134-x","volume":"9","author":"J He","year":"2021","unstructured":"He\u00a0J, Su\u00a0C, Liang\u00a0W, Xu\u00a0S, Wu\u00a0L, Fu\u00a0X, Zhang\u00a0X, Ge\u00a0D, Chen\u00a0Q, Mao\u00a0W, Xu\u00a0L, Chen\u00a0C, Hu\u00a0B, Shao\u00a0G, Hu\u00a0J, Zhao\u00a0J, Liu\u00a0X, Liu\u00a0Z, Wang\u00a0Z, Xiao\u00a0Z, Gong\u00a0T, Lin\u00a0W, Li\u00a0X, Ye\u00a0F, Liu\u00a0Y, Ma\u00a0H, Huang\u00a0Y, Zhou\u00a0J, Wang\u00a0Z, Fu\u00a0J, Ding\u00a0L, Mao\u00a0L, Zhou\u00a0C (2021) Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a\u00a0randomised, open-label, phase 3 trial. Lancet Respir Med 9(9):1021\u20131029. https:\/\/doi.org\/10.1016\/s2213-2600(21)00134-x","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1971_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40880-019-0414-4","volume":"39","author":"Z Zhang","year":"2019","unstructured":"Zhang\u00a0Z, Luo\u00a0F, Zhang\u00a0Y, Ma\u00a0Y, Hong\u00a0S, Yang\u00a0Y, Fang\u00a0W, Huang\u00a0Y, Zhang\u00a0L, Zhao\u00a0H (2019) The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Commun 39(1):69. https:\/\/doi.org\/10.1186\/s40880-019-0414-4","journal-title":"Cancer Commun"},{"issue":"5","key":"1971_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s1470-2045(19)30035-x","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito\u00a0H, Fukuhara\u00a0T, Furuya\u00a0N, Watanabe\u00a0K, Sugawara\u00a0S, Iwasawa\u00a0S, Tsunezuka\u00a0Y, Yamaguchi\u00a0O, Okada\u00a0M, Yoshimori\u00a0K, Nakachi\u00a0I, Gemma\u00a0A, Azuma\u00a0K, Kurimoto\u00a0F, Tsubata\u00a0Y, Fujita\u00a0Y, Nagashima\u00a0H, Asai\u00a0G, Watanabe\u00a0S, Miyazaki\u00a0M, Hagiwara\u00a0K, Nukiwa\u00a0T, Morita\u00a0S, Kobayashi\u00a0K, Maemondo\u00a0M (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20(5):625\u2013635. https:\/\/doi.org\/10.1016\/s1470-2045(19)30035-x","journal-title":"Lancet Oncol"},{"key":"1971_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03311-w","author":"T Landre","year":"2020","unstructured":"Landre\u00a0T, Guetz\u00a0DG, Chouahnia\u00a0K, Duchemann\u00a0B, Assi\u00e9\u00a0JB, Chouaid\u00a0C (2020) First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J\u00a0Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-020-03311-w","journal-title":"J Cancer Res Clin Oncol"},{"issue":"27","key":"1971_CR20","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1200\/jco.2016.66.9218","volume":"34","author":"Y Cheng","year":"2016","unstructured":"Cheng\u00a0Y, Murakami\u00a0H, Yang\u00a0PC, He\u00a0J, Nakagawa\u00a0K, Kang\u00a0JH, Kim\u00a0JH, Wang\u00a0X, Enatsu\u00a0S, Puri\u00a0T, Orlando\u00a0M, Yang\u00a0JC (2016) Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced Nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. Clin Oncol 34(27):3258\u20133266. https:\/\/doi.org\/10.1200\/jco.2016.66.9218","journal-title":"Clin Oncol"},{"issue":"1","key":"1971_CR21","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar\u00a0P, Wardak\u00a0Z, Gerber\u00a0DE, Tumati\u00a0V, Ahn\u00a0C, Hughes\u00a0RS, Dowell\u00a0JE, Cheedella\u00a0N, Nedzi\u00a0L, Westover\u00a0KD, Pulipparacharuvil S, Choy\u00a0H, Timmerman\u00a0RD (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA 4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","journal-title":"JAMA"},{"issue":"10","key":"1971_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jtho.2016.11.1439","volume":"14","author":"Y Xu","year":"2019","unstructured":"Xu Y, Zhang S, Xia B, Zhu L, Ma S (2019) Mechanism of radiotherapy in reduction\/delay of T790M-mediated EGFR TKI resistance. J Thorac Oncol 14(10):S1033. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.1439","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1971_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13014-021-01765-x","volume":"16","author":"W Jia","year":"2021","unstructured":"Jia\u00a0W, Gao\u00a0Q, Wang\u00a0M, Li\u00a0J, Jing\u00a0W, Yu\u00a0J, Zhu\u00a0H (2021) Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiat Oncol 16(1):41. https:\/\/doi.org\/10.1186\/s13014-021-01765-x","journal-title":"Radiat Oncol"},{"issue":"2","key":"1971_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","volume":"85","author":"DA Palma","year":"2013","unstructured":"Palma\u00a0DA, Senan\u00a0S, Tsujino\u00a0K, Barriger\u00a0RB, Rengan\u00a0R, Moreno\u00a0M, Bradley\u00a0JD, Kim\u00a0TH, Ramella\u00a0S, Marks\u00a0LB, De Petris\u00a0L, Stitt\u00a0L, Rodrigues\u00a0G (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85(2):444\u2013450. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.04.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1971_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ijrobp.2012.02.020","volume":"84","author":"H Liu","year":"2012","unstructured":"Liu\u00a0H, Zhang\u00a0X, Vinogradskiy\u00a0YY, Swisher\u00a0SG, Komaki\u00a0R, Chang\u00a0JY (2012) Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 84(4):1017\u20131023. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.02.020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1971_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cllc.2017.04.015","volume":"18","author":"T Jiang","year":"2017","unstructured":"Jiang\u00a0T, Cheng\u00a0R, Zhang\u00a0G, Su\u00a0C, Zhao\u00a0C, Li\u00a0X, Zhang\u00a0J, Wu\u00a0F, Chen\u00a0X, Gao\u00a0G, Li\u00a0W, Cai\u00a0W, Zhou\u00a0F, Zhao\u00a0J, Xiong\u00a0A, Ren\u00a0S, Zhang\u00a0G, Zhou\u00a0C, Zhang\u00a0J (2017) Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer 18(6):631\u2013639.e632. https:\/\/doi.org\/10.1016\/j.cllc.2017.04.015","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"1971_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cllc.2014.11.002","volume":"16","author":"YK Cha","year":"2015","unstructured":"Cha\u00a0YK, Lee\u00a0HY, Ahn\u00a0MJ, Choi\u00a0YL, Lee\u00a0JH, Park\u00a0K, Lee\u00a0KS (2015) Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Lung Cancer 16(3):228\u2013236. https:\/\/doi.org\/10.1016\/j.cllc.2014.11.002","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"1971_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger\u00a0M, Rowan\u00a0AJ, Horswell\u00a0S, Math\u00a0M, Larkin\u00a0J, Endesfelder\u00a0D, Gronroos\u00a0E, Martinez\u00a0P, Matthews\u00a0N, Stewart\u00a0A, Tarpey\u00a0P, Varela\u00a0I, Phillimore\u00a0B, Begum\u00a0S, McDonald\u00a0NQ, Butler\u00a0A, Jones\u00a0D, Raine\u00a0K, Latimer\u00a0C, Santos\u00a0CR, Nohadani\u00a0M, Eklund\u00a0AC, Spencer-Dene\u00a0B, Clark\u00a0G, Pickering\u00a0L, Stamp\u00a0G, Gore\u00a0M, Szallasi\u00a0Z, Downward\u00a0J, Futreal\u00a0PA, Swanton\u00a0C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N\u00a0Engl J Med 366(10):883\u2013892. https:\/\/doi.org\/10.1056\/NEJMoa1113205","journal-title":"N Engl J Med"},{"issue":"8","key":"1971_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3779\/j.issn.1009-3419.2015.08.02","volume":"18","author":"J Li","year":"2015","unstructured":"Li\u00a0J, Wu\u00a0X, Wang\u00a0Z, Shen\u00a0Z, Sun\u00a0N, Zhu\u00a0X (2015) Ionizing radiation reduces TKI resistance caused by T790M mutation in NSCLC cell lines. Chin J Lung Cance 18(8):475\u2013480. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2015.08.02","journal-title":"Chin J Lung Cance"},{"issue":"1","key":"1971_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jtho.2016.11.1439","volume":"12","author":"Y Xu","year":"2017","unstructured":"Xu\u00a0Y, Zhang\u00a0S, Xia\u00a0B, Zhu\u00a0L, Ma\u00a0S (2017) P2.05-005 mechanism of radiotherapy in reduction\/delay of T790M-mediated EGFR TKI resistance. J\u00a0Thorac Oncol 12(1):1033. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.1439","journal-title":"J Thorac Oncol"},{"issue":"20","key":"1971_CR31","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.7150\/jca.26364","volume":"9","author":"H Zhuang","year":"2018","unstructured":"Zhuang\u00a0H (2018) Research progress on the impact of radiation on TKI resistance mechanisms in NSCLC. J\u00a0Cancer 9(20):3797\u20133801. https:\/\/doi.org\/10.7150\/jca.26364","journal-title":"J Cancer"},{"key":"1971_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.12.009","volume":"140","author":"Y Tang","year":"2020","unstructured":"Tang\u00a0Y, Xia\u00a0B, Xie\u00a0R, Xu\u00a0X, Zhang\u00a0M, Wu\u00a0K, Wang\u00a0B, Ma\u00a0S (2020) Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer 140:65\u201370. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.009","journal-title":"Lung Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-01971-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:29:26Z","timestamp":1669415366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-01971-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-01971-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.\u00a0Deng, J.\u00a0Liu, T.\u00a0Song, T.\u00a0Xu, Y.\u00a0Li, L.\u00a0Duo, L.\u00a0Xiang, X.\u00a0Yu, J.\u00a0Lei and F.\u00a0Cao declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Patient medical records were analyzed retrospectively, with no individual patient identifiable information used. This work was approved by the ethics committee of Renmin Hospital, Hubei University of Medicine (No.: syrmyy2020\u2014034).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}